"Can myeloma patients use GLP-1 drugs for weight loss?" Beth Faiman breaks it down
Common side effects (affecting 20-40% of users) Nausea is the most frequently reported side effect, affecting roughly 30 to 40 percent of patients at some point during treatment
At this time, retatrutide, one of the best-known triple hormone receptor agonists, is still investigational and has not been approved by any regulatory agency for routine patient use
Moreover, in a study of 1200 patients admitted at ICU, of whom 203 were affected by diabetes, intensive insulin therapy significantly reduced the rate of morbidities, including newly acquired kidney injury and the need of mechanical ventilation, with accelerated discharge from the ICU and the hospital
An Evidence-Based Perspective (drlewis.com, January 4, 2026) Clinical perspective from practicing psychiatrist on integrating GLP-1s into psychiatric care, citing safety data and metabolic-mental health connection
Its main job is to help control blood sugar and appetite
